


Melanoma facts



What is melanoma?

Melanoma is an aggressive skin cancer that originates from melanocytes,1 which are cells in the skin and eyes that produce and contain melanin.2

Melanoma develops when unrepaired DNA damage to melanocytes triggers mutations that cause the melanocytes to grow rapidly and form malignant tumors.

Metastatic melanoma

is melanoma that has spread to other parts of the body.

What is the global incidence and mortality of melanoma?

most common malignancy in the United States³ increment in annual cases of melanoma4 **Deadliest** cutaneous cancer

In 2020: 324,635 new cases and 57,043 deaths worldwide⁵



minutes

person dies from skin cancer The World Health Organization predicts that from 2020 to 2025, the number of deaths resulting from melanoma

will increase by 20% rising to 74% by 2040

What are the risk factors?

Lifetime UV exposure is the most important environmental risk factor⁶

Age

Incidence rates increase after age 60³

Skin **Damage**

History of blistering sunburns

Cancer

Family history of melanoma or other skin cancer

Skin tone

Fair skin pigmentation at higher risk4

Moles

Presence of atypical moles4



Why is early diagnosis important?

Melanoma survival rates



Localized melanoma is highly curable

with a simple surgical excision.

Early stage survival rates are 99% whereas late stage is quite poor at 30%.7

Delaying treatment of a Stage 1 (localized) melanoma by just one month increases the risk of death by 5%.4

As it grows in the span of just a few millimeters, the melanoma's lethality increases markedly.

How is melanoma diagnosed?

Abnormal skin lesion* "ABCDE" criteria3

A= Asymmetry of a mole or birthmark

B= Border irregularity

C= Color variation D= Diameter is >6mm

E= Evolving size, shape, color, bleeding or scabbing

Diagnostic excisional biopsy Standard of care for suspicious pigmented

skin lesions³

Clinical correlation High percentage of

melanomas diagnosed histologically which were not identified on clinical examination8

H&E is the primary tool for melanoma diagnostic evaluation and IHC the main complementary tool

Melanocytic versus non-melanocytic

Benign versus Malignant

he most frequent subtype; for other less common subtypes, diagnostic pathways may be different. **There are no p16 IHC tests labeled for use in evaluation of melanomas.

In-situ versus Invasive

> Complementary tools

IHC: HMB45, MART1/

MelanA, S-100, SOX-109

PRAME, p16 IHC," HMB-45, KI-67, cytogenetic

Deeper levels, MART1/MelanA, SOX-10 tools, FISH9, Gene Expression Profile10

HMB45, MART1/MelanA, p16, are considered supportive to the morphologic diagnosis but not diagnostic per se. 11

What should I do to reduce my potential for developing melanoma?



Wear sun protective clothing, a hat and sunglasses



Apply sunscreen and re-apply often especially after swimming

1. Chopra A. et al. Surg Clin N Am. 2020; Feb;100(1):43-59. 2. www.cancer.gov (accessed May 26, 2022). 3. Newcomer K. et al. Current Problems in Surgery. 2022; 59:101030. 4. 2020 Melanoma Skin Cancer Report. Available at https://melanomapatients.org.au) (accessed June 12, 2022). 5. Cazzato G. et al. Genes. 2022;13: 545. 6. Garbe C., et al. European Journal of Cancer. 2020; 126:141e-158. 7. American Cancer Society.

Available at https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html (accessed June 12, 2022). 8. Melanoma CAP Protocol.

Version 4.3.1.0 9. Harvey N., Wood B. Arch Pathol Lab Med. 2019;143:789-810. 10. Andea A. Histolpathology. 2022;80(1):150-165. 11. Santandrea G., et al. Am J Surg Pathol. 2022;46:579-590.



Make evaluation of your skin a routine and discuss any changes with your physician/dermatologist



Educate yourself

and others

MC-US-11979-1022